Nomura Holdings
KPTI icon

Nomura Holdings’s Karyopharm Therapeutics KPTI Stock Holding History

Nomura Holdings’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-12,153
Closed -$158K – 1848
2023
Q4 		$158K Hold
12,153
– – ﹤0.01% 1614
2023
Q3 		$244K Buy
+12,153
New +$273K ﹤0.01% 1221

Other funds holding KPTI

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
APM
Avidity Partners Management Dallas, Texas $936M AUM 195% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
EP
Eversept Partners New York $1.9B AUM 121.13% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nomura Holdings's KPTI Position: Q4 2023 in Review

Nomura Holdings sold out of Karyopharm Therapeutics (KPTI) in Q4 2023, closing a stake of 1,296 shares — an estimated $17.5K sold.

Nomura Holdings first reported a position in KPTI in Q1 2020 and held it in 2 quarters. The position peaked at $835K in Q1 2020. 117 funds tracked by Wall St. Rank hold KPTI as of Q4 2023.

  • Nomura Holdings reported no remaining Karyopharm Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Nomura Holdings sold 1,296 Karyopharm Therapeutics shares in Q4 2023, an estimated $17.5K.
  • Nomura Holdings first reported a position in Karyopharm Therapeutics in Q1 2020 and held it in 2 quarters.
  • Nomura Holdings's Karyopharm Therapeutics position peaked at $835K in Q1 2020.
  • 117 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q4 2023.

Based on Nomura Holdings's 13F filing for Q4 2023, filed 14 Feb 2024.